STAT+: Lilly wins approval for once-weekly insulin shot

The lead item is Eli Lilly's approval win for a once-weekly insulin shot — a dosing advance for diabetes patients, though the full STAT+ analysis sits behind a paywall. The roundup also notes that STAT reporter Jason Mast is in Shanghai covering biotech news.

In legal news, a jury in a California federal court found that Eli Lilly breached a contract with Nektar Therapeutics to co-develop the autoimmune disease drug rezpeg in good faith. The jury awarded Nektar $90 million in damages plus interest — an amount far less than the company had been seeking.

On the regulatory front, FDA commissioner nominee Heidi Overton largely avoided declaring her stance on several issues during a contentious Senate confirmation hearing. Pressed on vaccines, abortion, and whether she would resist political pressure from President Trump or health secretary Robert F. Kennedy Jr., she repeatedly pointed to existing law and agency policy rather than giving direct answers.